ArticleEpilepsia2026
Clinical outcomes following stereotactic MRI-guided laser ablation in children with tuberous sclerosis complex and intractable epilepsy.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn children with tuberous sclerosis complex (TSC) and drug-resistant epilepsy (DRE), magnetic resonance imaging-guided stereotactic laser ablation (SLA) therapy offers less-invasive treatment compared to craniotomy and resection. Our study seeks to further expand on the long-term outcomes in patients with TSC-related DRE who have undergone SLA.
methodsPatients with TSC and DRE treated with SLA, between July 1, 2016 and January 1, 2022, at our institution were identified retrospectively. Reduction in number of anti-seizure medications (ASMs), developmental improvement as reported by the patients' families, seizure frequency measured in surgically targeted seizure type and total seizures per day, and Engel classification were evaluated at 6 months, 1 year, 2 years, and thereafter at the most recent follow-up visit if available.
resultsForty patients (ages 11 months to 23 years, median age 3.6 years) with TSC underwent SLA. Total follow-up was on average 2.9 years post-surgery. Significant (>50%) reduction in total seizure frequency occurred in 80% of patients (n = 32), with 63% of patients reporting a >90% reduction in seizure frequency (n = 25) at last follow-up. Fifty-eight percent had complete freedom from their surgically targeted seizure type (n = 23). At last follow up, perceived developmental gains occurred in 63% (n = 25), reduction in ASM occurred in 40% (n = 16), and Engel class was III or less in 93% of patients (n = 37). SIGNIFICANCE: SLA was safe and effective for most patients, even the very young. A majority of patients achieved improvement in seizure frequency, including the surgically targeted seizure type, but less than half were able to reduce medications. Reported developmental improvement was related to Engel outcomes. Future studies utilizing neuropsychological testing in the full cohort will be required to offer objective insights into post-operative development profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.